依达拉奉联合前列地尔治疗不稳定型心绞痛的临床研究

Clinical Research on Edaravone Combined with Alprostadil in Treating Unstable Angina Pectoris

目的观察依达拉奉联合前列地尔治疗不稳定型心绞痛的临床疗效。方法将90例不稳定型心绞痛患者随机分为对照组和观察组,每组45例。对照组给予常规监护及常规药物治疗;观察组在对照基础上给予依达拉奉联合前列地尔静脉滴注治疗,两组患者均持续治疗2周。观察比较两组临床疗效,治疗前、治疗7天后、治疗14天后血清hs-CRP水平,出院1个月后患者24h内缺血发作次数、总缺血时间、心肌缺血总负荷时间。结果观察组较对照组治疗有效率明显提高(P<0.05)。治疗第7天、14天,观察组较对照组血清hs-CRP水平均明显降低(P<0.05)。出院1个月后,观察组缺血发作次数、总缺血时间、心机缺血总负荷均明显少于对照组(P<0.05)。结论依达拉奉联合前列地尔治疗不稳定型心绞痛疗效肯定,可降低患者血清hs-CRP水平,改善心肌缺血状况,提高治疗有效率,值得临床推广。

Objective To observe the clinical curative effects of edaravone combined with alprostadil in treating unstable angina pectoris. Methoda 90 cases of patients with unstable angina pectoris were randomly divided into contrast group and observation group with each group 45 cases. Patients in the contrast group were given conventional custody and conventional drug therapy, while patients in the observation group were given edaravone combined with alprostadil intravenous drip treatment based on the treatment that contrast group conducted. Patients in both groups were given continuous treatment for 2 weeks. Observe and compare the clinical curative effects as well as the serum hs- CRP level of before treatment, 7d after treatment and 14d after treatment. 1 month after discharging hospital, all the patients were given 24h dynamic ECG. Compare the frequency of transient ischemia attack, total ischemia time and total load time of myocardial ischemia between both groups.Results The total effective rate in the observation group was significantly higher than the contrast group（P〈0.05）. 7d and 14d after treatment, the serum hs-CRP levels in the observation group were respectively significantly decreased than the contrast group（P〈0.05）. 1 month after discharging hospital, the frequency of transient ischemia attack, total ischemia time and total load time of myocardial ischernia in the observation group were all significantly decreased than the contrast group（P〈0.05）. Conclusion Edaravone combined with alprostadil is proved to be effective in treating unstable angina pectoris, which helps to decrease the serum hs-CRP level, improve the myocardial ischemia condition and increase the total effective rate. Thus, it deserves to be widely promoted in clinical field.